Amanda Forys: The Need for Clarity in Biosimilars
Amanda Forys, MSPH, discusses the critical lack of clarity in the US biosimilars marketplace.
Amanda Forys: CMS Reimbursement Codes for Biosimilars
Amanda Forys, MSPH, senior director of reimbursement policy insights at Xcenda, discusses current reimbursement policy for biosimilars.
Molly Burich: Industry Challenges with Biosimilars
Molly Burich, MS, associate director of public policy: biosimilars, pipeline, and reimbursement at Boehringer Ingelheim, discusses the challenges the industry faces with respect biosimilars.
Challenges Ahead for Biosimilars
Upcoming Patent Litigation in Biosimilars
The Need for Clarity After <i>Sandoz v Amgen</i>
The PTAB's Role in Biosimilar Patent Disputes
State Laws and Biosimilar Substitution
Healthcare Reform Efforts and the BPCIA
CMS and Blended Reimbursement Codes
Biosimilar Uptake and Health Plans
Biosimilars, Formularies, Contracting, and PBMs
Reforms at the FDA Level
Inspection Reports and Proprietary Information
Global Reference Products in Biosimilar Development
Biosimilars, Interchangeability, and Perceptions of Safety
Interchangeability and Rheumatology Prescribing Practices
Biosimilar Interchangeability and Market Share
Dr Angus Worthing: Congressional Budget Allocation for Healthcare
Angus Worthing, MD, FACR, FACP, discusses the need for adequate funding for the FDA and healthcare.
Robert Cerwinski: Hatch-Waxman Litigation of Follow-On Insulins
Robert Cerwinski, JD, partner at Goodwin, explains why Hatch-Waxman litigation may provide a smoother path than does the Biologics Price Competition and Innovation Act.
Robert Cerwinski: Oil States and the Inter Partes Review Process
Robert Cerwinski, JD, partner at Goodwin, discusses a petition before the Supreme Court challenging the constitutionality of inter partes review.
Dr Brandon Shank: Pharmacy School Curriculum and Biosimilars
Brandon Shank, PharmD, MPH, BCOP, Clinical Pharmacy Specialist, discusses the need for pharmacy schools to adapt their curriculum to address biosimilar treatments.
Robert Cerwinski: Pay-for-Delay Settlements and Agency Scrutiny
Robert Cerwinski, JD, partner at Goodwin, discusses the potential for government agencies to weigh in on pay-for-delay settlements in the biosimilars space.
Dr Brandon Shank: Reimbursement Challenges With Biosimilars
Brandon Shank, PharmD, MPH, BCOP, Clinical Pharmacy Specialist, discusses the potential for reimbursement challenges with biosimilars.
Dr Bruce A. Feinberg: Patient Education on Biosimilars
Bruce A. Feinberg, DO, CMO, Cardinal Health Specialty Solutions, discusses the importance of patient education on biosimilar treatments.
Robert Cerwinski: The Impact of TC Heartland on Biosimilar Litigation
Robert Cerwinski, JD, Partner at Goodwin, discusses the impact of the recent Supreme Court ruling in TC Heartland v Kraft on biosimilar litigation.
Dr Brandon Shank: Biosimilar Naming and Suffixes
Brandon Shank, PharmD, MPH, BCOP, Clinical Pharamcy Specialist, discusses the merits of the current biosimilar naming system.
Dr Kashyap Patel: Biosimilars and Medicare Part D Drug Pricing
Kashyap Patel, MD, Medical Oncologist, Carolina Blood and Cancer Care, discusses the potential impact of biosimilar drugs on Medicare Part D drug pricing.
Dr Marcus Snow: Automatic Substitution of Biosimilars in Rheumatology
Marcus H. Snow, MD, Assistant Professor Rheumatology, University of Nebraska, discusses concerns about automatic substitution of biosimilars for reference products.
Robert Cerwinski: Current Infliximab Litigation
Robert Cerwinski, JD, Partner at Goodwin, discusses current infliximab litigation.
